Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, age 18 years or older~* Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic, accelerated, or blast phase~* Patients will have either failed, demonstrated intolerance, or a combination of prior failure and intolerance, to prior treatments with at least two tyrosine kinase inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a response) or secondary resistance (loss of response).~* Acceptable Renal and Liver Function~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~* Sexually active patients and their partners must use an effective double barrier method of contraception~Exclusion Criteria:~* New York Heart Association classification (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition~* Myocardial infarction in the previous 12 weeks.~* Other concurrent illness which would preclude study conduct and assessment~* uncontrolled and active infection, and positive HIV or positive HTLV I/II status, whether on treatment or not.~* Pregnant or lactating.~* Any medical or psychiatric condition, which may compromise the ability to give written informed consent or to comply with the study protocol.~* Lymphoid Ph+ blast crisis~* Patient is enrolled in another clinical investigation within 30 days of enrollment or is receiving another investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMA (Type: EXPERIMENTAL): Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m\^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m\^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).